Peptonic Medical announces a partly underwritten rights issue of 12.5 MSEK
Stockholm, April 10th, 2018 - The Board of Peptonic Medical AB (publ) (’Peptonic’ or ’Company’) today announced a rights issue of 12.5 MSEK with pre-emptive rights for existing shareholders.
The issue is underwritten by shareholders and external guarantors to 9,4 MSEK (75%).
Issue price is 0,29 SEK per share, which values the company at 12,5 MSEK.
Last day of trading including pre-emptive rights is April 13, 2018. Subscription period is April 19 – May 4, 2018.
For further details please refer to the company’s webpage or to your investment bank.
The stock is listed on Aktietorget (www.aktietorget.se) with ISIN no SE0005962206.
CEO’s comment;
“One year ago we were at a road’s crossing. The in-house developed vaginal gel without oxytocin showed remarkably good treatment effects in the clinical study, which made us decide to launch a non-prescription (OTC) product under the trademark VagiVital®. During the past year we have worked hard to prepare for the launch and we have gained useful insights of the market. The CE mark for VagiVital® is expected in the near future and then the road to the market is open. We expect to have established the brand on the home market within a year. Discussions regarding distribution outside Sweden are underway. Hence, we are facing exciting times as we are now launching the first commercial product in the history of Peptonic.”
Johan Inborr, CEO
Advisors
Partner Fondkommission AB are the financial advisors of Peptonic Medical in this transaction.
For more information, please contact:
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail: johan.inborr@peptonicmedical.se
About Peptonic Medical
PEPTONIC Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital™ is a trademark of PEPTONIC Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of PEPTONIC Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin®is on hold pending additional data on i.a. the mechanism of action.
In July 2014, PEPTONIC Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com
About VagiVital®
VagiVital®is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
PEPTONIC Medical plans to launch VagiVital®as a non-prescription self-care product in 2018.